Updated Clinical Practice Guidelines Available Online
To: All Providers
The following Clinical Practice Guidelines have been reviewed and approved by our Quality Management Committee (QMC) and can be viewed online at bcbswny.com/provider > Policies & Guidelines > Practice Guidelines.
New guideline added:
o Dementia - The American College of Physicians and American Academy of Family Physicians developed this guideline to present the available evidence on current pharmacologic treatment of dementia. https://www.aafp.org/dam/AAFP/documents/patient_care/clinical_recommendations/Dementia-Clinical-Practice-Guideline.pdf
The targeted literature search included evidence related to the effectiveness of five U.S. Food and Drug Administration approved pharmacologic therapies for dementia for outcomes in the domains of cognition, global function, behavior/mood, and quality of life/activities of daily living.
1. Clinicians should base the decision to initiate a trial of therapy with a cholinesterase inhibitor or memantine on individualized assessment. (Grade: weak recommendation, moderate-quality evidence.)
2. Clinicians should base the choice of pharmacologic agents on tolerability, adverse effect profile, ease of use, and cost of medication. The evidence is insufficient to compare the effectiveness of different pharmacologic agents for the treatment of dementia. (Grade: weak recommendation, low-quality evidence.)
3. There is an urgent need for further research on the clinical effectiveness of pharmacologic management of dementia.
Guidelines with no content changes:
- Attention Deficit Hyperactivity Disorder (ADHD)
- Cardiovascular Disease (Atrial Fibrillation; Cholesterol/CAD; Risk Assessment and Primary Prevention; Hypertension; Heart Failure; and Stroke)
- Chronic Kidney Disease (CKD)
- Falls Prevention
- Hip and Knee
- Obstructive Sleep Apnea (OSA)
- Palliative Care
- Right Start Maternity/Prenatal
- Sexually Transmitted Diseases (STDs)
- Substance Use Disorder
- Tobacco Cessation
Guidelines with content changes:
- Chronic Obstructive Pulmonary Disease (COPD)
- Initial treatment (based on the ABCD Assessment Tool) was separated from follow-up treatment.
- Blood eosinophil count added as a biomarker for estimating the efficacy of inhaled corticosteroids for the prevention of exacerbations.
- Moved under Cardiovascular Disease section
Updated preventive health guidelines are also available for:
- Adolescents (birth to 18 years)
- Adult (men and women)
- Immunizations (childhood and adult)
To request a paper copy, please call 1-877-878-8785, option 2. Leave your name, address, and the specific guideline you are requesting.
Working with Us
We want to hear from you! Have a topic request for the next Blue Bulletin? Email us
Stay in Touch! Sign up to receive emails for provider news and information